Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV Walmsey-1 Infection
Best insight from top research papers
Dolutegravir plus lamivudine has shown high effectiveness and tolerability in treating HIV-1 infection. Studies have demonstrated that this combination is well-tolerated, effectively suppresses HIV-1 RNA levels, and leads to significant improvements in patients' conditions. Notably, in patients with ultra-high viral loads, the dolutegravir plus lamivudine regimen has proven to be a promising treatment option, with no significant differences in achieving viral suppression compared to lower viral load groups. The combination of dolutegravir and lamivudine has been effective in both treatment-naive and treatment-experienced individuals, showcasing its efficacy and safety profile in real-world settings.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
01 Oct 2022 | Not addressed in the paper. |
| Not addressed in the paper. | |
| Not addressed in the paper. | |
| Not addressed in the paper. | |
| Abacavir/dolutegravir/lamivudine combination therapy is effective and well-tolerated for treating HIV-1 infection, as shown in a Korean post-marketing study. |
Related Questions
What are the benefits of using Abacus software?4 answersThe benefits of using Abacus software include its usefulness and efficiency in both regional and at-site statistical analyses of Annual Maxima (AM) time series. It allows for easy comparison of sample skewness with pre-determined Monte Carlo Prediction Intervals, providing indications about possible clusters and regional values for parameters. For at-site analyses, Abacus offers the possibility of calibrating one function for some parameters of the others, reducing computational costs. Additionally, Abacus has been shown to be effective in improving students' performance in learning fractions through digital games-based learning. It provides an alternative method for teaching fractions and may inspire the integration of digital games-based learning in educational settings. Abacus is also a generic resource management framework that addresses the problem of inefficient allocations of cloud resources in existing cloud systems. It allows users to specify their priorities and job characteristics, leading to optimal allocation and scheduling of resources.
Why dolutegravir is affec child less than 17 years whays?3 answersDolutegravir has been studied for its use in children living with HIV. It has been found to be safe and effective in children weighing less than 20 kg, with appropriate drug exposure and no safety concerns. However, there are limited and conflicting data on the impact of dolutegravir on weight gain in children and adolescents. In a study conducted in Mozambique, it was found that viral suppression rates of ≥80% were achieved with dolutegravir, but there were multiple anchor drug switches for over one-third of children, possibly due to drug stockouts. A population pharmacokinetic analysis showed that a once-daily 50 mg dose of dolutegravir produced adequate concentrations in children and adolescents when used in combination with ritonavir-boosted darunavir. Overall, dolutegravir has shown promise as a treatment option for children and adolescents with HIV, but further research is needed to fully understand its effects on weight gain and long-term outcomes in this population.
Does only abacavir be altered peptide repertoire?4 answersAbacavir has been shown to alter the peptide repertoire presented by HLA-B*57:01 molecules. It binds non-covalently to the floor of the peptide binding groove of HLA-B*57:01, leading to changes in the shape and chemistry of the antigen-binding cleft. This alteration in the antigen-binding cleft results in the selection of new endogenous peptides, inducing an "altered self". This altered self activates abacavir-specific T-cells, leading to a systemic reaction known as abacavir hypersensitivity syndrome (AHS). Additionally, carbamazepine, another drug associated with hypersensitivity reactions, has also been shown to alter the repertoire of presented self peptides in individuals with the HLA-B*15:02 allele. Therefore, both abacavir and carbamazepine have been shown to cause alterations in the peptide repertoire presented by specific HLA alleles.
Does GLP1 antidiabetics affect weight in patients with HIV?5 answersGLP-1 antidiabetic drugs have been shown to affect weight in patients with HIV. In a study comparing different antidiabetic treatments in type 2 diabetes patients, GLP-1 treatment was found to be comparable to metformin in terms of weight reduction, while sulfonylurea and DPP-4 inhibitors were inferior in this regard. Another study in patients living with HIV found that treatment with GLP-1 receptor analogues (aGLP1) resulted in weight loss after one year of treatment. These findings suggest that GLP-1 antidiabetic drugs can have a positive impact on weight management in patients with HIV.
What are the advantages and disadvantages of using atazanavir to treat HIV?5 answersAtazanavir (ATV) has several advantages as a treatment for HIV. It is administered once daily and has been shown to decrease opportunistic infections in people living with HIV (PLHIV). However, there are also disadvantages associated with ATV therapy. One common adverse effect is hyperbilirubinemia, with a high incidence reported in many studies. Risk factors for hyperbilirubinemia include abnormal baseline total bilirubin levels and coadministration of certain drugs such as raltegravir. On the other hand, coadministration of tenofovir or efavirenz seemed to decrease the risk of hyperbilirubinemia. Additionally, ATV has been shown to bind to and modulate the activity of the type 2 ryanodine receptor (RyR2), which can potentially increase the risk of ventricular arrhythmias and sudden cardiac death in PLHIV. Therefore, while ATV has its advantages in HIV treatment, the risk of hyperbilirubinemia and potential cardiac effects should be considered when selecting antiretroviral agents.
Does stavudine have an impact on CD4 count in patients with HIV?4 answersStavudine has been found to have an impact on CD4 count in patients with HIV. One study showed a decline in CD4 count in HIV patients treated with stavudine. Another study found that stavudine-based highly active antiretroviral therapy (HAART) was associated with impaired mitochondrial respiratory function in CD4+ peripheral blood lymphocytes (PBLs). However, a study on switching to a lower dose of stavudine showed that reducing the dose increased CD4 count and improved mitochondrial indices while maintaining HIV suppression. A randomized trial on stavudine and ribavirin coadministration in HIV-HCV coinfected patients found no short-term impact on CD4 count. A study conducted in Surabaya, Indonesia found no significant difference in CD4 count between patients with and without opportunistic infections. Overall, stavudine treatment can have an impact on CD4 count in HIV patients, but the specific effects may vary depending on factors such as dose and coadministration with other drugs.